171 related articles for article (PubMed ID: 17004091)
21. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).
Randazzo M; Müller A; Carlsson S; Eberli D; Huber A; Grobholz R; Manka L; Mortezavi A; Sulser T; Recker F; Kwiatkowski M
BJU Int; 2016 Apr; 117(4):576-83. PubMed ID: 26332304
[TBL] [Abstract][Full Text] [Related]
22. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
23. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
[TBL] [Abstract][Full Text] [Related]
24. [Epidemiology of familial prostatic cancer: 4-year assessment of French studies].
Valeri A; Drelon E; Azzouzi R; Delannoy A; Teillac P; Fournier G; Mangin P; Berthon P; Cussenot O
Prog Urol; 1999 Sep; 9(4):672-9. PubMed ID: 10555220
[TBL] [Abstract][Full Text] [Related]
25. Role of Genetic Polymorphisms in the Development and Prognosis of Sporadic and Familial Prostate Cancer.
Reis ST; Viana NI; Leite KR; Diogenes E; Antunes AA; Iscaife A; Nesrallah AJ; Passerotti CC; Srougi V; Pontes-Junior J; Salles ME; Nahas WC; Srougi M
PLoS One; 2016; 11(12):e0166380. PubMed ID: 27906997
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
27. Pathological features of hereditary prostate cancer.
Bastacky SI; Wojno KJ; Walsh PC; Carmichael MJ; Epstein JI
J Urol; 1995 Mar; 153(3 Pt 2):987-92. PubMed ID: 7853589
[TBL] [Abstract][Full Text] [Related]
28. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
29. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice.
Amling CL; Blute ML; Lerner SE; Bergstralh EJ; Bostwick DG; Zincke H
Mayo Clin Proc; 1998 May; 73(5):401-6. PubMed ID: 9581578
[TBL] [Abstract][Full Text] [Related]
30. Characteristics of patients with familial versus sporadic prostate cancer.
Roehl KA; Loeb S; Antenor JA; Corbin N; Catalona WJ
J Urol; 2006 Dec; 176(6 Pt 1):2438-42; discussion 2442. PubMed ID: 17085123
[TBL] [Abstract][Full Text] [Related]
31. Clinical and pathologic characteristics of familial prostate cancer in Asian population.
Kim M; Kim JK; Ye C; Lee H; Oh JJ; Lee S; Jeong SJ; Lee SE; Hong SK; Byun SS
Prostate; 2020 Jan; 80(1):57-64. PubMed ID: 31664733
[TBL] [Abstract][Full Text] [Related]
32. [Genetic, epidemiologic and clinical study of familial prostate cancer].
Valéri A
Bull Acad Natl Med; 2002; 186(4):779-88; discussion 788-91. PubMed ID: 12412374
[TBL] [Abstract][Full Text] [Related]
33. [Patients with prostate cancer after radical prostatectomy: Stage migration and changes in tumor characteristics from 1998-2012].
Walther A; Kron M; Klorek T; Gschwend JE; Herkommer K
Urologe A; 2016 Feb; 55(2):167-75. PubMed ID: 26471796
[TBL] [Abstract][Full Text] [Related]
34. Prostate carcinoma with positive margins at radical prostatectomy: role of tumour zonal origin in biochemical recurrence.
O'Neil LM; Walsh S; Cohen RJ; Lee S
BJU Int; 2015 Oct; 116 Suppl 3():42-8. PubMed ID: 26218868
[TBL] [Abstract][Full Text] [Related]
35. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
[TBL] [Abstract][Full Text] [Related]
36. Residual prostatic tumour in the surgical bed following radical prostatectomy in organ-confined prostate cancer: possible prognostic significance.
Valotto C; Falconieri G; Pizzolitto S; Cerruto MA; Brondani G; De Gobbi A; Zattoni F
Arch Ital Urol Androl; 2011 Jun; 83(2):78-82. PubMed ID: 21826879
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
[TBL] [Abstract][Full Text] [Related]
38. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
39. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
40. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
